Bovine TB and Johne’s Disease are two devastating livestock diseases. PBD Biotech’s diagnostic Actiphage® is an accurate and specific blood test for these diseases.
Hear about development of an improved diagnostic for bTB and Johne’s Disease on 6th July
PBD Biotech gains £2.3m funding to take Actiphage through to OIE validation, a requirement for international adoption of this diagnostic for mycobacterial diseases including bTB, Johne’s Disease and human TB
Actiphage®, a rapid, accurate test for tuberculosis that detects the presence of the live mycobacteria in a sample of blood or milk, has been awarded the Innovation Award 2021 by Veterinary Record, the official journal of the British Veterinary Association (BVA).
Johne’s disease costs the Canadian dairy industry an estimated $90 million a year through loss of production. PBD Biotech has gained funding from the Canadian government to progress development of its unique Actiphage test for mycobacterial diseases to address this major economic issue.
Vet Robert Price-Jones comments in a BBC interview that the blood test Actiphage offers the potential for eradicating bovine TB from the farm: “Early identification of animals at risk of bovine TB enables effective disease management and control.”
PBD Biotech’s Actiphage technology wins Royal Dairy Innovation Award 2019
Powerful diagnostics, using the latest science, are offering a new approach to disease management, explains PBD Biotech CEO Berwyn Clarke
A year since he first pitched in the REAP Start-Up Showcase (right), Dr Berwyn Clarke, Co-founder of PBD Biotech, was back to announce the first